Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
Essai Randomise Comparant Deux Stategies De Chimiotherapie Dans Les Cancers Pancreatiques Avances: LV5FU2 Simplifie + Cisplatine Suivi de Gemcitabine, Versus Gemcitabine Suivi de LV5FU2 Simplifie + Cisplatine en Can de Progression
Sponsor: Federation Francophone de Cancerologie Digestive
Listed as NCT00303758, this PHASE3 trial focuses on Pancreatic Cancer and remains completed. Sponsored by Federation Francophone de Cancerologie Digestive, it has been updated 7 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Oct 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Oct 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Federation Francophone de Cancerologie Digestive
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Abbeville, France , Avignon, France , Blois, France , Boulogne, France , Boulogne-sur-Mer, France , Bourg-en-Bresse, France , Bourgoin, France , Caen, France , Châlons-en-Champagne, France , Clermont-Ferrand, France and 31 more locations